Surgery Partners Inc (SGRY)
NASDAQ:SGRY
Want to see SGRY full AI Analyst Report?
Top Page
Surgery Partners
(NASDAQ:SGRY)
Select Model
Select Model
Rating:57Neutral
Price Target:
$14.50
▲(3.57% Upside)
Action:ReiteratedDate:05/05/26
SGRY scores mid-range primarily due to improving but still inconsistent fundamentals—strong revenue growth and positive operating cash flow are offset by persistent losses and a recent free-cash-flow setback. Technicals are moderately supportive in the short term but the longer-term trend remains negative. Valuation is constrained by the negative P/E, while the latest call’s reiterated guidance is constructive but tempered by leverage, interest expense, and demand/mix headwinds.
Positive Factors
Revenue and scale growth
Sustained and accelerating revenue growth has expanded Surgery Partners' scale across ASCs and surgical hospitals, improving bargaining leverage with payers and suppliers and enabling reinvestment in higher‑acuity service lines. Larger scale supports margin recovery, network optimization, and longer‑term M&A optionality.
Negative Factors
Persistent GAAP losses and negative EBITDA
Ongoing GAAP losses and episodic negative EBITDA indicate that top‑line gains have not fully converted to sustainable profitability. This raises execution risk on cost control, margin durability and the company's ability to produce consistent GAAP returns as it scales, prolonging reliance on noncash adjustments and operational fixes.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and scale growth
Sustained and accelerating revenue growth has expanded Surgery Partners' scale across ASCs and surgical hospitals, improving bargaining leverage with payers and suppliers and enabling reinvestment in higher‑acuity service lines. Larger scale supports margin recovery, network optimization, and longer‑term M&A optionality.
Read all positive factors
Surgery Partners (SGRY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.84B
Dividend YieldN/A
Average Volume (3M)1.27M
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth6.24%
EPS Growth53.98%
CountryUS
Employees15,000
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.61
Shares Outstanding129,419,830
10 Day Avg. Volume930,329
30 Day Avg. Volume1,267,615
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)1.15
Price to Sales (P/S)0.59
P/FCF Ratio10.05
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue0.62
Enterprise Value/Gross Profit2.66
Enterprise Value/Ebitda2.14
Forecast
1Y Price Target
$19.55Price Target Upside39.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.39
Revenue Forecast (FY)$3.41B
Surgery Partners Business Overview & Revenue Model
Company Description
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its sur...
How the Company Makes Money
Surgery Partners generates revenue primarily by providing surgical and related healthcare services through its owned and operated facilities. The core revenue stream is patient service revenue: the company bills commercial insurers, Medicare, Medi...
Surgery Partners Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Neutral
Neutral — The call conveyed cautious optimism: the company reported solid revenue and EBITDA in line with expectations, strong MSK/robotics momentum, physician recruiting progress and reiterated full‑year guidance, but those positives are counterbalanced by below‑trend case growth, payer mix/provider tax headwinds, rising interest expense and elevated leverage that temper near‑term upside.Positive Updates
Quarterly Financial Performance in Line with Expectations
Net revenue of approximately $811 million; adjusted EBITDA of approximately $102 million (12.6% adjusted EBITDA margin); same‑facility net revenue growth of 4.4%; operating cash flow of ~$12 million (vs ~$6 million prior year).
Negative Updates
Below‑Trend Same‑Facility Case Growth
Same‑facility case growth was only 0.6% in Q1 (well below the company’s long‑term algorithm and vs ~6.5% in Q1 2025); management attributed part of the shortfall (~40 basis points) to weather‑related deferrals in higher‑volume, lower‑acuity markets (e.g., GI, ophthalmology).
Read all updates
Q1-2026 Updates
Positive
Negative
Quarterly Financial Performance in Line with Expectations
Net revenue of approximately $811 million; adjusted EBITDA of approximately $102 million (12.6% adjusted EBITDA margin); same‑facility net revenue growth of 4.4%; operating cash flow of ~$12 million (vs ~$6 million prior year).
Read all positive updates
Company Guidance
Surgery Partners reiterated full-year 2026 guidance of $3.35 billion to $3.45 billion of revenue and adjusted EBITDA of at least $530 million (not including any potential M&A), and said Q2 should represent roughly 24%–24.5% of annual revenue and 23%–23.5% of annual adjusted EBITDA; they continue to target ~$200 million of annual capital deployment for M&A but deployed only ~$4 million in Q1 (estimated to add ~$7 million of 2026 revenue). For context, Q1 results included about $811 million of net revenue, ~$102 million of adjusted EBITDA (12.6% margin), same‑facility revenue growth of 4.4% and case growth of 0.6%, supply expense of ~27.2% of revenue, SWB ~30.5%, other operating expenses ~7.3%, DSO ~66 days, operating cash flow ~$12 million (vs. $6M prior year), maintenance capex ~$9 million, physician distributions $58 million, net leverage ~4.3x (credit agreement) and GAAP net debt/adjusted EBITDA ~5.1x; other metrics discussed include ~140 physicians recruited in Q1, 73 surgical robots in the portfolio, total‑joint ASC growth of 14.6% YoY, and an estimated full‑year headwind from provider taxes/Medicaid cuts of roughly $8 million.Surgery Partners Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
64
Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.31B | 3.11B | 2.74B | 2.54B | 2.23B |
| Gross Profit | 765.00M | 745.60M | 647.50M | 574.90M | 491.40M |
| EBITDA | 565.50M | 501.40M | 446.10M | 460.00M | 401.00M |
| Net Income | -77.90M | -168.10M | -11.90M | -54.60M | -70.90M |
Balance Sheet | |||||
| Total Assets | 8.24B | 7.89B | 6.88B | 6.68B | 6.12B |
| Cash, Cash Equivalents and Short-Term Investments | 239.90M | 269.50M | 195.90M | 282.90M | 389.90M |
| Total Debt | 4.02B | 3.70B | 3.06B | 2.93B | 3.29B |
| Total Liabilities | 4.72B | 4.25B | 3.51B | 3.40B | 3.82B |
| Stockholders Equity | 1.71B | 1.79B | 1.99B | 2.00B | 1.09B |
Cash Flow | |||||
| Free Cash Flow | 195.60M | 209.70M | 205.00M | 78.20M | 29.50M |
| Operating Cash Flow | 274.30M | 300.10M | 293.80M | 158.80M | 87.10M |
| Investing Cash Flow | -246.60M | -488.50M | -225.60M | -307.90M | -331.70M |
| Financing Cash Flow | -57.30M | 262.00M | -155.20M | 42.10M | 316.30M |
Surgery Partners Technical Analysis
Neutral
14.00
Price Trends
13.50
Positive
14.69
Negative
18.06
Negative
Market Momentum
0.06
Negative
66.75
Neutral
94.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGRY, the sentiment is Neutral. The current price of 14 is above the 20-day moving average (MA) of 12.47, above the 50-day MA of 13.50, and below the 200-day MA of 18.06, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 66.75 is Neutral, neither overbought nor oversold. The STOCH value of 94.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SGRY.
Surgery Partners Risk Analysis
Surgery Partners disclosed 41 risk factors in its most recent earnings report. Surgery Partners reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Surgery Partners Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $2.66B | 21.34 | 11.57% | 1.80% | 17.53% | 17.13% | |
71 Outperform | $10.58B | 12.33 | 24.48% | 0.65% | 10.05% | 23.59% | |
67 Neutral | $15.97B | 5.83 | 34.82% | ― | 4.56% | 27.14% | |
64 Neutral | $10.13B | 7.84 | 20.93% | 0.35% | 9.71% | 36.69% | |
58 Neutral | $94.77B | 16.55 | -123.20% | 0.61% | 6.71% | 29.32% | |
57 Neutral | $1.84B | -32.76 | -4.50% | ― | 6.24% | 53.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SGRY
Surgery Partners
14.20
-8.81
-38.29%
HCA
HCA Healthcare
427.18
72.86
20.56%
EHC
Encompass Health
106.64
-9.61
-8.26%
NHC
National Healthcare
170.61
77.42
83.08%
THC
Tenet Healthcare
185.35
33.87
22.36%
UHS
Universal Health
166.07
-17.36
-9.47%
Surgery Partners Corporate Events
Business Operations and StrategyStock BuybackFinancial Disclosures
Surgery Partners Announces Share Buyback and 2026 Outlook
Positive
Mar 2, 2026
Surgery Partners reported fourth-quarter 2025 revenue of $885.0 million, up 2.4% year over year, with same-facility revenue rising 3.5% but overall surgical cases declining 2.1% as Adjusted EBITDA slipped 4.2% to $156.9 million. For full-year 2025...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.